Breadcrumb Home Studies Studies Search Filter Research Area AllComplications & ComorbiditiesCureTreatmentTuberculosis Study Status AllClosed to AccrualClosed to Follow UpConcludedEnrollingIn DevelopmentParticipants Off Study and Primary Analysis CompletedPending Sort Study Number AscStudy Number Desc Submit Search Showing 14 studies. IMPAACT 2046: UPLIFT Study DAIDS Number TBA Research Area Brain and Mental Health Study Status In Development IMPAACT 2039: EXCEED DAIDS Number 38,988 Research Area Cure and Immunotherapy Study Status In Development IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1 DAIDS Number 38962 Research Area Therapeutics Study Status Pending IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States DAIDS Number 38746 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Enrolling IMPAACT 2021: Randomized Phase I/II Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/ delta 1313/I1314L, RSV 6120/ delta NS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age DAIDS Number 38530 Research Area Cure and Immunotherapy Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2018: Randomized Phase I Study of the Infectivity, Safety, and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/delta 1313/I1314L or RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age DAIDS Number 38405 Research Area Complications & Comorbidities Study Status Concluded IMPAACT 2013: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, D46/NS2/N/delta M2-2-HindIII, Lot RSV#011B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age DAIDS Number 30074 Research Area Complications & Comorbidities Study Status Concluded IMPAACT 2012: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID cp delta M2-2, Lot RSV#009B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age DAIDS Number 30073 Research Area Complications & Comorbidities Study Status Concluded IMPAACT 2011: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID delta M2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age DAIDS Number 30072 Research Area Complications & Comorbidities Study Status Concluded Pagination Current page 1 Page 2 Next page Next
IMPAACT 2046: UPLIFT Study DAIDS Number TBA Research Area Brain and Mental Health Study Status In Development
IMPAACT 2039: EXCEED DAIDS Number 38,988 Research Area Cure and Immunotherapy Study Status In Development
IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1 DAIDS Number 38962 Research Area Therapeutics Study Status Pending
IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States DAIDS Number 38746 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Enrolling
IMPAACT 2021: Randomized Phase I/II Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/ delta 1313/I1314L, RSV 6120/ delta NS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age DAIDS Number 38530 Research Area Cure and Immunotherapy Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2018: Randomized Phase I Study of the Infectivity, Safety, and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/delta 1313/I1314L or RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age DAIDS Number 38405 Research Area Complications & Comorbidities Study Status Concluded
IMPAACT 2013: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, D46/NS2/N/delta M2-2-HindIII, Lot RSV#011B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age DAIDS Number 30074 Research Area Complications & Comorbidities Study Status Concluded
IMPAACT 2012: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID cp delta M2-2, Lot RSV#009B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age DAIDS Number 30073 Research Area Complications & Comorbidities Study Status Concluded
IMPAACT 2011: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID delta M2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age DAIDS Number 30072 Research Area Complications & Comorbidities Study Status Concluded
